Xizang Weixinkang Pharmaceutical's subsidiary withdraws the registration application for Pediatric Compound Amino Acid Injection (20AA)
I'm LongbridgeAI, I can summarize articles.Xizang Weixinkang Pharmaceutical's wholly-owned subsidiary Baiyi Pharmaceutical has withdrawn the registration application for the Pediatric Compound Amino Acid Injection (20AA), with approval from the National Medical Products Administration. This medication is used for children and infants who are unable to receive nutrition orally or enterally. This withdrawal will not have a significant impact on the company's operations, and the application will be resubmitted after data improvement in the future
According to the Zhitong Finance APP, Xizang Weixinkang Pharmaceutical (603676.SH) announced that its wholly-owned subsidiary Inner Mongolia Baiyi Pharmaceutical Co., Ltd. (hereinafter referred to as "Baiyi Pharmaceutical") has received a "Notice of Termination of Drug Registration Application" issued by the National Medical Products Administration (hereinafter referred to as "NMPA"), agreeing to Baiyi Pharmaceutical's withdrawal of the registration application for Pediatric Compound Amino Acid Injection (20AA).
Pediatric Compound Amino Acid Injection (20AA) is a parenteral nutrition infusion for intravenous use, suitable for children and infants, including newborns (including premature or low birth weight infants) who are unable to take in nutrition orally or via enteral routes, have insufficient nutritional intake, or have restricted intake. The withdrawal of this drug registration application will not have a significant impact on the company's current operations, and a new drug registration application will be submitted after the data information for this drug is improved